Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients

Kidney International

Volumn 58, Issue 4, 2000, Pages 1742-1750

  Covic, Adrian M C ^a,b   Schelling, Jeffrey R ^a,b   Constantiner, Marigel ^a,b   Iyengar, Sudha K ^a,b   Sedor, John R ^a,b  

^a METROHEALTH MEDICAL CENTER   (United States)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Classifying diabetics; Genetic epidemiology; Heredity; IDDM; Insulin secretion; NIDDM; Progressive renal injury

Indexed keywords

C PEPTIDE; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE CLASSIFICATION; FEMALE; GENETIC EPIDEMIOLOGY; HEMODIALYSIS; HEREDITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRIORITY JOURNAL;

EID: 0033797528     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00335.x     Document Type: Article

References (48)

1. Mapping genes for NIDDM: Design of the Finland-United States investigation of NIDDM genetics (fusion) study
2. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: Clustering of long-term complications in families with diabetes in the diabetes control and complications trial (DCCT)
3. The classification of diabetes by clinical and C-peptide criteria: A prospective population-based study
4. UK PROSPECTIVE DIABETES STUDY GROUP: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes
5. Latent autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency
6. Renal findings in patients with short term type 2 diabetes
7. Novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes related antibodies
8. Diabetes and atherosclerosis: The role of insulin
9. Ingested interferon alpha suppresses type I diabetes in non-obese mice
10. In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes
11. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice
12. TROGLITAZONE AND EXOGENOUS INSULIN STUDY GROUP: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus
13. The incidence of end-stage renal disease in type I and type II diabetes mellitus
14. Similar risk of nephropathy in patients with type I or type II diabetes mellitus
15. Genetic analysis of NIDDM: The study of quantitative traits
16. Genetic determinants of diabetic nephropathy
17. Genetics of diabetic nephropathy: Evidence for major and minor gene effects
18. Genetic susceptibility to end-stage renal disease
19. Genetic dissection of complex traits
20. Genetic dissection of complex traits: Guidelines for interpreting and reporting linkage results
21. Classification of diabetes in patients with end-stage renal disease
22. C-peptidkonzentration im serum in abhangigkeit von der nierenfunktion
23. Plasma C-peptide in uraemic patients
24. Plasma levels of proinsulin, insulin and C-peptide in chronic renal, hepatic and muscular disorders
25. Day long integrated serum insulin and C-peptide profiles in patients with NIDDM: Correlation with urinary and C-peptide excretion
26. Renal metabolism of C-peptide in patients with early insulin-dependent diabetes mellitus
27. AMERICAN DIABETES ASSOCIATION EXPERT COMMITTEE: Report of the expert committee on the diagnosis and classification of diabetes mellitus
28. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes
29. Epidemiology, development and treatment of endstage renal failure in type 2 (non insulin-dependent) diabetes mellitus
30. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes
31. Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus
32. Comparison of the course to end stage renal disease of type 1 (insulin dependent) and type 2 (non insulin dependent) diabetic nephropathy
33. Self-monitoring of blood glucose by adults with diabetes in the United States population
34. Plasma concentrations and transperitoneal transport of native insulin and C-peptide in patients on continuous ambulatory peritoneal dialysis
35. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis
36. Plasma and urinary C-peptide in the classification of adult diabetics
37. Discriminative capacity of fasting C-peptide levels in a functional test according to different criteria of response to a stimulus: A study of Brazilian insulin-dependent diabetic patients
38. Clinical and biochemical characteristics of type 2 diabetic patients on continuous ambulatory peritoneal dialysis: Relationship with insulin requirement
39. Estimating prevalence of type 1 and type 2 diabetes in a population of African Americans with diabetes mellitus
40. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus
41. Factors influencing beta-cell function and insulin sensitivity in patients with type 2 (non-insulin-dependent) diabetes. Acta Endrocrinol (Copenh)
42. Factors associated with fasting and postglucagon plasma C-peptide levels in middle-aged insulin treated diabetic patients
43. Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-quiring based on clinical and biochemical variables
44. Pharmacokinetics of oral glyburide in subjects with non-insulin dependent diabetes mellitus and renal failure
45. Metabolism of pro-insulin, insulin and C-peptide in the rat
46. Renal elimination of islet amyloid polypeptide